Despite the remarkable increase in medications validated as effective in bipolar disorder, treatment is still plagued by inadequate response in acute manic or depressive episodes or in long-term preventive maintenance treatment. Established first-line treatments include lithium, valproate and second-generation antipsychotics (SGAs) in acute mania, and lithium and valproate as maintenance treatments. Recently validated treatments include extended release carbamazapine for acute mania and lamotrigine, olanzapine and aripiprazole as maintenance treatments. For treatment-resistant mania and as maintenance treatments, a number of newer anticonvulsants, and one older one, phenytoin, have shown some promise as effective. However, not all anticonvulsants are effective and each agent needs to be evaluated individually. Combining multiple agents is the most commonly used clinical strategy for treatment resistant bipolar patients despite a relative lack of data supporting its use, except for acute mania (for which lithium or valproate plus an SGA is optimal treatment). Other approaches that may be effective for treatment-resistant patients include high-dose thyroid augmentation, clozapine, calcium channel blockers and electroconvulsive therapy (ECT). Adjunctive psychotherapies show convincing efficacy using a variety of different techniques, most of which include substantial attention to education and enhancing coping strategies. Only recently, bipolar depression has become a topic of serious inquiry with the dominant controversy focusing on the place of antidepressants in the treatment of bipolar depression. Other than mood stabilizers alone or the combination of mood stabilizers and antidepressants, most of the approaches for treatment-resistant bipolar depression are relatively similar to those used in unipolar depression, with the possible exception of a more prominent place for SGAs, prescribed either alone or in combination with antidepressants. Future work in the area needs to explore the treatments commonly used by clinicians with inadequate research support, such as combination therapy and the use of antidepressants as both acute and adjunctive maintenance treatments for bipolar disorder.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Molecular Psychiatry Open Access 13 July 2021
International Journal of Bipolar Disorders Open Access 04 May 2019
International Journal of Bipolar Disorders Open Access 31 May 2017
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Judd JL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530–537.
Judd JL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261–269.
MacQueen GM, Young LT, Joffe RT . A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand 2001; 103: 163–170.
Gitlin MJ, Swendsen J, Heller TL, Hammen C . Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635–1640.
Gitlin MJ, Hammen C . Syndromal and psychosocial outcome in bipolar disorder: a complex and circular relationship. In: Goldberg J (ed). Bipolar Disorders: Clinical Course and Outcome. American Psychiatric Press: Washington, DC, 1999, pp 39–55.
Gitlin MJ . Treatment of refractory depression. In: Licinio JWL (ed). Biology of Depression. Wiley VCH: New York, 2004, pp 385–410.
Burt T, Sachs GS, Demopulos C . Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 1998; 45: 959–964.
Schaffer A, Levitt AJ, Joffe RT . Mexiletine in treatment-resistant bipolar disorder. J Affect Disord 2000; 57: 249–253.
Sachs GS . Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215–236.
Colom F, Vieta E, Martinez-Aran A, Reinares M, Beinabarre A, Gasto C . Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000; 61: 549–555.
Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481–489.
Tohen M, Bowden C, Calabrese J, Sachs GS, Jacobs T, Baker RW et al. Olanzapine vs placebo for relapse prevention in bipolar disorder. Presented at the 156th annual meeting of the American Psychiatric Association. San Francisco, CA, 2003 (Abstract NR197).
Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432–441.
Keck PE, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP . Treatment of bipolar disorder 2004: the expert consensus guideline series. Postgrad Med Special Report 2004; 1–120.
Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66: 870–886.
Hirschfeld RMA, Bowden CL, Gitlin MJ, Keck PE, Perlis RH, Suppes T et al. American Psychiatric Association Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(Suppl 4): 1–50.
Weisler RH, Kalali AH, Ketter TA, SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 478–484.
Weisler RH, Keck PE, Swann AC, Cutler AJ, Ketter TA, Kalali AH et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005; 66: 323–330.
Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400.
Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013–1024.
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month randomized, double-blind controlled clinical trial. Am J Psychiatry 2005; 162: 1281–1290.
Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263–1271.
McQuade R, Sanchez R, Marcus R, Carson W, Rollin L, Iwamoto T et al. Aripiprazole for relapse prevention in bipolar disorder: a 26-week placebo controlled study. Int J Neuropsychopharmacol 2004; 7(Suppl 2): S161.
Goldsmith DR, Warstaff AJ, Ibbotson T, Perry CM . Lamotrigine: a review of its use in bipolar disorder. Drugs 2003; 63: 2029–2050.
Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH . Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000; 157: 463–465.
Mishory A, Winokur M, Bersudsky Y . Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord 2003; 5: 464–467.
Yatham LN . New anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004; 65(Suppl 10): 28–35.
Friss ML, Kristenson O, Boos J, Dalby M, Deth SH, Gram L et al. Therapeutic experience with 947 epileptic outpatients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224–227.
Saria CA, Remedi C . Levetiracetam as mood stabilizer in the treatment of pharmacogenomic hypomania in bipolar disorder II in elderly patients. Int J Neuropsychopharmacol 2002; 5(Suppl 1): S57.
Grunze H, Langosch J, Born C, Schaub G, Walden J . Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003; 64: 781–784.
Bersani G . Levetiracetam in bipolar spectrum disorders: first evidence of efficacy in an open, add-on study. Human Psychopharmacol Clin Exp 2004; 19: 355–356.
Post RM, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 2005; 66: 370–374.
Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki JI et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 707–715.
Anand A, Bukhari L, Jennings SA, Lee C, Kamat M, Shekhar A et al. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. J Clin Psychiatry 2005; 66: 195–198.
McElroy SL, Suppes T, Keck PE, Black D, Frye M, Altshuler LL et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry 2005; 66: 617–624.
Marcotte D . Use of topiramate, a new antiepileptic as a mood stabilizer. J Affect Disord 1998; 50: 245–251.
Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–733.
Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 1658–1669.
Power PS, Sachs GS, Kushner SF, Wang D, Olson W, Capece J et al. Topiramate in adults with acute bipolar I mania. Posted results, presented at the 157th annual meeting of the American Psychiatric Association, New York, NY, 2004 (abstract NR 365).
Delbello MP, Finding RL, Kushner S, Wang D, Olson WH, Capece JA et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 539–547.
McIntyre RS, Riccardelli R, Binder C, Kusumakar V . Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can J Psychiatry 2005; 50: 415–422.
Pande AC, Crockett J, Janney CA, Werth SL, Tsauroucha G . Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2: 249–255.
Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osach EA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607–614.
Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it done to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol 2002; 22: 584–591.
Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J . Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60: 759–762.
Schaffer LC, Schaffer CB, Howe J . An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 2002; 71: 259–263.
Suppes T, Chisholm KA, Dhavale D, Frye MA, Altshuler LL, McElroy SL et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 2002; 4: 283–289.
Levine J, Chengappa KNR, Brar JS, Gershon S, Yablonsky E, Stapf D et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000; 2: 120–130.
Nolen WA, Luckenbaugh DA, Altshuler LL, Suppes T, McElroy SL, Frye MA et al. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley foundation bipolar network. Am J Psychiatry 2004; 161: 1447–1454.
Bowden C . Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 2004; 65(Suppl 15): 21–24.
Müller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J . Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol 2000; 20: 195–203.
Tohen M, Chengappa KNR, Suppes T, Baker RW, Zarate CA, Bowden CL et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337–345.
Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58: 95–99.
Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM . Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470–478.
Freeman MP, Stoll AL . Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998; 155: 12–21.
Bauer MS, Whybrow PC . Rapid cycling bipolar affective disorder II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435–440.
Baumgartner A, Bauer M, Hellweg R . Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. Neuropsychopharmacology 1994; 10: 183–189.
Bauer M, Hellweg R, Gräf KJ, Baumgartner A . Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998; 18: 444–455.
Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology 2002; 27: 620–628.
Gyalai L, Bauer M, Espona-Garcia F, Hierholzer J, Baumgartner A, Berghöfer A et al. Bone mineral density in pre- and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001; 66: 185–191.
Bauer M, Fairbanks L, Berghöfer A, Hierholzer J, Bschor T, Baethge C et al. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study. J Affect Disord 2004; 83: 183–190.
Frye MA, Ketter TA, Altshuler LL, Denicoff K, Dunn RT, Kimbrell TA et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91–104.
Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64: 451–458.
Fehr BS, Ozcan ME, Suppes T . Low doses of clozapine may stabilize treatment-resistant bipolar patients. Eur Arch Psychiatry Clin Neurosci 2005; 255: 10–14.
Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ . Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164–1169.
Mukherjee S, Sackeim HA, Schnur DB . Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994; 151: 169–176.
Zornberg GL, Pope HG . Treatment of depression on bipolar disorder: new directions for research. J Clin Psychpharmacol 1993; 13: 397–408.
Vaidya NA, Mahableshwarkar AR, Shahid R . Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT 2003; 19: 10–16.
Small JG, Klapper MH, Kellams JJ, Miller MJ, Milstein V, Sharpley PH et al. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1998; 45: 727–732.
Mukherjee S, Sackeim HA, Lee C . Unilateral ECT in the treatment of manic episodes. Convuls Ther 1988; 4: 74–80.
Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407–412.
Osher Y, Bersudsky Y, Belmaker RH . Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open label study. J Clin Psychiatry 2005; 66: 726–729.
Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Keck PE et al. An overview of recent findings of the Stanley foundation bipolar network (part I). Bipolar Disord 2003; 5: 310–319.
Levy NA, Janicak PG . Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord 2000; 2: 108–119.
Dubovsky SL, Franks RD, Allen S, Murphy J . Calcium antagonists in mania: a double-blind study of verapamil. Psychiatry Res 1986; 18: 309–320.
Lenzi A, Marazziti D, Raffaelli S, Cassano GB . Effectiveness of the combination verapamil and chlorpromazine in the treatment of severe manic or mixed patients. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 519–528.
Walton SA, Berk M, Brook S . Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. J Clin Psychiatry 1996; 57: 543–546.
Janicak PG, Sharma RP, Pandey G, Davis JM . Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. Am J Psychiatry 1998; 155: 972–973.
Wisner KL, Peindl KS, Perel JM, Hanusa BH, Piontek CM, Baab S . Verapamil treatment for women with bipolar disorder. Biol Psychiatry 2002; 51: 745–752.
Goodnick PJ . The use of nimodipine in the treatment of mood disorders. Bipolar Disord 2000; 2: 165–173.
Brunet G, Cerlich B, Robert S, Dumas S, Souetre E, Darcourt G . Open trial of a calcium antagonist nimodipine in acute mania. Clin Neuropharmacol 1990; 13: 224–228.
Pazzaglia PJ, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 1998; 18: 404–413.
Curtin F, Schulz P . Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord 2004; 78: 201–208.
Garvey MJ, Hwang S, Teubner-Rhodes D, Zander J, Rhem C . Dextroamphetamine treatment of mania. J Clin Psychiatry 1987; 48: 412–413.
Schaffer A, Levitt AJ . Double-blind, placebo-controlled pilot study of mexiletine for acute mania or hypomania. J Clin Psychopharmacol 2005; 25: 507–508.
Colom F, Vieta E . A perspective on the use of psychoeducation, cognitive-behavioral therapy and interpersonal therapy for bipolar patients. Bipolar Disord 2004; 6: 480–486.
Scott J, Gutierrez MJ . The current status of psychological treatments in bipolar disorders: a systematic review of relapse prevention. Bipolar Disord 2004; 6: 498–503.
Gutierrez MJ, Scott J . Psychological treatment for bipolar disorders: a review of randomised controlled trials. Eur Arch Psychiatry Clin Neurosci 2004; 254: 92–98.
Miklowitz D, Goldstein MJ . Bipolar Disorder: A Family Focused Approach. Guilford Press: New York, NY, 1997.
Miklowitz DJ, Simoneau TL, George EL, Richards JA, Kalbag A, Sachs-Ericsson N et al. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000; 48: 582–592.
Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL . A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003; 60: 904–912.
Rea MM, Tompson MC, Miklowitz DJ, Goldstein MJ, Hwang S, Mintz J . Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. J Consult Clin Psychol 2003; 71: 482–492.
Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 60: 145–152.
Lam DH, Hayward P, Watkins ER, Wright K, Sham P . Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. Am J Psychiatry 2005; 162: 324–329.
Colom F, Vieta E, Martínez-Arán A, Reinares M, Goikolea JM, Benabarre A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402–407.
Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005; 62: 996–1004.
Miklowitz DJ, Richards JA, George EL, Frank E, Suddath RL, Powell KB et al. Integrated family and individual therapy for bipolar disorder: results of a treatment development study. J Clin Psychiatry 2003; 64: 182–191.
Calabrese JR, Bowden CL, Sachs G, Ascher JA, Monaghan E, Rudd GD . A double-blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88.
Yatham LN, Calabrese JR, Kusumakar V . Bipolar depression: criteria for treatment selection, definition of refractoriness and treatment options. Bipolar Disord 2003; 5: 85–97.
Keck PE, Nelson EB, McElroy SL . Advances in the pharmacologic treatment of bipolar depression. Biol Psychiatry 2003; 53: 671–679.
Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM . Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161: 1537–1547.
Dubovsky SL . Treatment of bipolar depression. Psychiatr Clin North Am 2005; 28: 349–370.
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C et al. Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–1088.
Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK . Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003; 5: 421–433.
Möller HJ, Grunze H . Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 2000; 250: 57–68.
Sachs GS, Collins MA, Altshuler LL, Ketter TA, Suppes T, Rasgon NL et al. Divalproex sodium versus placebo for the treatment of bipolar depression. Presented at the 40th annual meeting of the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico, 2001.
Davis LL, Bartolucci A, Petty F . Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85: 259–266.
Ernst CL, Goldberg JF . Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol 2003; 23: 182–192.
McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH . Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 4: 207–213.
Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–1360.
Goldberg JF, Burdick KE, Endick CJ . Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564–566.
Zarate CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54–60.
Carlson PJ, Merlock MC, Suppes T . Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 2004; 6: 416–420.
Frye MA, Grunze H, Suppes T, Mc Elroy SL, Denicoff K, Keck PE et al. Modafinil in the treatment of bipolar depression: A placebo-controlled trial. Presented at the annual meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, HI, 2005.
Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18: 435–440.
Amsterdam J . Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18: 414–417.
Amsterdam JD, Garcia-Espana F . Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 2000; 59: 225–229.
Amsterdam JD, Shults J, Brunswick DJ, Hundert M . Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression – low manic switch rate. Bipolar Disord 2004; 6: 75–81.
Amsterdam JD, Shults J . Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005; 20: 257–264.
Amsterdam JD, Shults J . Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression – lack of manic induction. J Affect Disord 2005; 87: 121–130.
Altshuler LL, Kiriakos L, Calcagno J, Goodman R, Gitlin M, Frye M et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001; 62: 612–616.
Altshuler LL, Suppes T, Black D, Nolen WA, Keck PE, Frye MA et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160: 1252–1262.
About this article
Cite this article
Gitlin, M. Treatment-resistant bipolar disorder. Mol Psychiatry 11, 227–240 (2006). https://doi.org/10.1038/sj.mp.4001793
- bipolar disorder
- antimanic agents
- bipolar depression
- medication combinations
This article is cited by
Molecular Psychiatry (2022)
The Potential Use of Peripheral Blood Mononuclear Cells as Biomarkers for Treatment Response and Outcome Prediction in Psychiatry: A Systematic Review
Molecular Diagnosis & Therapy (2021)
International Journal of Bipolar Disorders (2019)
Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study
International Journal of Bipolar Disorders (2017)